FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:613-626 August 7, 2008 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set CME Exam Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Non-Hodgkin's lymphoma is the most common hematologic cancer in adults, with more than 66,000 incident cases anticipated in the United States in 2008.¹ Approximately 85% of non-Hodgkin's lymphomas in adults are of B cell origin.² Some B-cell non-Hodgkin's lymphomas are indolent, or slow-growing, yet incurable. In contrast, others are aggressive or very aggressive, and may be rapidly fatal, yet are often curable.

There has been a revolution in the treatment of B-cell non-Hodgkin's lymphomas, owing largely to the availability of therapeutic monoclonal antibodies. The concept that antibodies might be effective for the treatment of cancers originated more than a century . . . [Full Text of this Article]

Rationale for the Use of Monoclonal Antibodies in B-Cell Lymphomas

Mechanisms of Action

Resistance to Monoclonal Antibodies

Antiidiotype Antibodies

Rituximab for Follicular and Low-Grade Lymphoma

Antibodies as Maintenance Therapy

Chemoimmunotherapy for Diffuse Large-B-Cell Non-Hodgkin's Lymphoma

Combinations of Antibody Therapy and Chemotherapy in Mantle-Cell Lymphoma

Radioimmunotherapy

⁹⁰Y-Labeled Ibritumomab Tiuxetan

¹³¹I-Labeled Tositumomab

Toxicity of Radioimmunotherapy

Other Antibodies

Anti-CD20 Antibodies in Development

Alemtuzumab

Galiximab

Anti-CD40 Antibodies

Epratuzumab

Lumiliximab

Hu1D10

Other Antibody Approaches

Future Directions

Source Information

From the Division of Hematology-Oncology, Georgetown University Hospital, Washington, DC (B.D.C.); and the Center for Lymphoma and Myeloma, Weill Cornell Medical College, New York (J.P.L.).

Address reprint requests to Dr. Cheson at Georgetown University Hospital, 3800 Reservoir Rd., NW, Washington, DC 20007, or at bdc4@georgetown.edu.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.